Försäljningstillväxt 64% y/y Försäljningen uppgick till 53,1 mkr vs vårt estimat om 43,6 mkr.
Redeye was hoping for a bit more in terms of sales given the strong growth trend during the second h...
Redeye retains its positive view on Sdiptech following a Q1 report in line with our expectations.
Redeye retains its positive stance towards Vertiseit following a Q1 report beating our forecasts reg...
Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes seve...
Redeye maintains its fair value range unchanged – the quarterly financials were in line with expecta...
Redeye argues that the changed financial target is relatively unaffecting the long-term case for Sed...
Redeye’s preliminary revisions suggest adjustments to Hoylu’s 2022E and 2023E, as its Q1’22 figures ...
Adj. Q1 sales +79% q-o-q and +45% vs. ABGSCe… …but lower gross margins than expected Ovzon-3 to be l...
Redeye changes its sales forecast and fair value range after weaker-than-expected sales for Q1 while...
Enersense’s Q1 profitability figures beat our estimates but cost inflation can hurt figures more dur...
Exel’s EBIT appears bound to improve more from the recent lows.
Strong Q1’22 beat – revenues 54% higher than cons. New orders in Q1, driven by higher-margin segment...
Solid operational performance and project progress +100bps interest rate to our ’24e impacts CEPS by...
The underlying demand for Vaisala’s applications continued strong.
We expected soft Q1 sales due to the Omicron wave in early Q1.
Europe and RoW improving both sales and adj. EBITA Strong gross (59.
Strong aftermarket recovery behind 40% org. growth Russian sales offset by stronger aftermarket; EBI...
Redeye returns with a second comment following Alelion’s Q1(22) report with actual figures in line w...
Sdiptech delivered a solid Q1 report, with EBITA* in line with our expectations.
